Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 12/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.70 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.55 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | PIR | O00625 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.55 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.55 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.55 |
| ▸ | STK16 | O75716 | 1/20 | 0.55 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | FES | P07332 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | YES1 | P07947 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288248 | 0.89 | CYP2C19 (0.61) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL297886 | 0.87 | BRAF (0.73) | CYP3A4CYP2C19CYP2C9BMPR1BPLK4 | |
| SCHEMBL288162 | 0.87 | CYP3A4 (0.64) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL297112 | 0.86 | CYP3A4 (0.71) | CYP3A4CYP2C19CYP2C9BMPR1BPLK4 | |
| SCHEMBL288222 | 0.86 | CYP2C19 (0.60) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL287654 | 0.86 | CYP2C19 (0.74) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL1085097 | 0.85 | CYP3A4 (1.00) | CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL10246477 | 0.85 | CYP3A4 (0.66) | CYP3A4CYP2C19CYP2C9BMPR1BPLK4 | |
| SCHEMBL287717 | 0.85 | CYP2C19 (0.68) | CYP3A4CYP2C19CYP2C9BRAF | |
| SCHEMBL1820202 | 0.85 | CYP3A4 (0.86) | CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153641-B2 | Pyrrolo(2,3-d)pyrimidine kinase inhibitors; melanoma, colorectal cancer, pain, polycystic kidney disease and other Raf protein kinase related conditions; e.g. Propane-1-sulfonic acid[3-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro-phenyl]-amide; Raf kinases including B-raf, A-raf | PLEXXIKON INC. (US) | 2012-04-10 | — | — | US | claimed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-8153641-B2 | Pyrrolo(2,3-d)pyrimidine kinase inhibitors; melanoma, colorectal cancer, pain, polycystic kidney disease and other Raf protein kinase related conditions; e.g. Propane-1-sulfonic acid[3-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro-phenyl]-amide; Raf kinases including B-raf, A-raf | PLEXXIKON INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153641-B2 | Pyrrolo(2,3-d)pyrimidine kinase inhibitors; melanoma, colorectal cancer, pain, polycystic kidney disease and other Raf protein kinase related conditions; e.g. Propane-1-sulfonic acid[3-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro-phenyl]-amide; Raf kinases including B-raf, A-raf | PLEXXIKON INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153641-B2 | Pyrrolo(2,3-d)pyrimidine kinase inhibitors; melanoma, colorectal cancer, pain, polycystic kidney disease and other Raf protein kinase related conditions; e.g. Propane-1-sulfonic acid[3-(4-cyclopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2,4-difluoro-phenyl]-amide; Raf kinases including B-raf, A-raf | PLEXXIKON INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2009143024-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286783-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, PRKACA, RAF1 | CYP3A4 3358/4885CYP2C19 2661/4885CYP2C9 2304/4885 |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP3A4 3611/4885CYP2C19 2730/4885CYP2C9 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.